α4β7 peptide monomer and dimer antagonists

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9809623
SERIAL NO

14872975

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against α4β1 binding, and have high stability under gastrointestinal conditions.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
PROTAGONIST THERAPEUTICS INC7707 GATEWAY BOULEVARD NEWARK CA 94560-1160

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Bhandari, Ashok Pleasanton, US 67 947
Liu, David Milpitas, US 263 5445
Mattheakis, Larry C Cupertino, US 39 878
Patel, Dinesh V Fremont, US 71 1372
Zemede, Genet San Jose, US 26 448

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 7, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 7, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00